Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;89(3):347-361.
doi: 10.1007/s00280-021-04390-3. Epub 2022 Jan 26.

Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies

Danesh Hassani  1 , Mahmood Jeddi-Tehrani  2 , Parisa Yousefi  2 , Samaneh Mansouri-Fard  1 , Maryam Mobini  1 , Hengameh Ahmadi-Zare  2 , Forough Golsaz-Shirazi  1 , Mohammad Mehdi Amiri  3 , Fazel Shokri  4
Affiliations

Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies

Danesh Hassani et al. Cancer Chemother Pharmacol. 2022 Mar.

Abstract

Purpose: The therapeutic potential of targeting the human epidermal growth factor receptor-3 (ErbB3/HER3) has long been ignored due to impaired tyrosine kinase function and low expression level in tumor cells compared with EGFR and HER2. Although recent investigations have explored the potential benefit of HER3 targeting and several anti-HER3 agents have been developed, there is still a critical need to design and produce more efficient therapeutics. This study was designed to develop tumor inhibitory monoclonal antibodies (MAbs) against different extracellular subdomains of HER3.

Methods: Distinct extracellular subdomains of HER3 (DI+II and DIII+IV) were utilized to produce MAbs by hybridoma technology. Biochemical and functional characteristics of these MAbs were then investigated by various methodologies, including immunoblotting, flow cytometry, cell proliferation, cell signaling, and enzyme-linked immunosorbent assays.

Results: Four anti-DI+II and six anti-DIII+IV MAbs were obtained, selected based on their ability to bind recombinant full HER3 extracellular domain (ECD). Our data showed that only one anti-DI+II and four anti-DIII+IV MAbs recognized the native form of HER3 by immunoblotting. Four MAbs recognized the membranous HER3 by flow cytometry leading to induction of different levels of receptor internalization and subsequent degradation. Results of cell proliferation assays using these MAbs indicated that they differentially inhibited proliferation of HER3-expressing cancer cells and showed considerable synergistic effects in combination with trastuzumab. Selected MAb with the highest inhibitory effect significantly inhibited the phosphorylation of AKT and ERK1/2 molecules.

Conclusion: Some of the anti-HER3 MAbs produced in this study displayed tumor inhibitory function and may be considered promising candidates for future HER3-targeted cancer therapy.

Keywords: Cancer therapy; ErbB3; HER3; Hybridoma; Monoclonal antibodies.

PubMed Disclaimer

References

    1. Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65(10):1566–1584. https://doi.org/10.1007/s00018-008-7440-8 - DOI - PubMed - PMC
    1. Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT (2018) HER3 signaling and targeted therapy in cancer. Oncol Rev 12(1):45–62. https://doi.org/10.4081/oncol.2018.355 - DOI
    1. Gala K, Chandarlapaty S (2014) Molecular pathways: HER3 targeted therapy. Clin Cancer Res 20(6):1410–1416. https://doi.org/10.1158/1078-0432.CCR-13-1549 - DOI - PubMed - PMC
    1. Kol A, Terwisscha van Scheltinga AGT, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EGE, Schröder CP (2014) HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacol Ther 143(1):1–11. https://doi.org/10.1016/j.pharmthera.2014.01.005 - DOI - PubMed
    1. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ErbB2 and discovering ErbB3. Nat Rev Cancer 9(7):463–475. https://doi.org/10.1038/nrc2656 - DOI - PubMed

Publication types

LinkOut - more resources